Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients

Bibliography

• Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (COPD). National Heart Lung and Blood Institute/World Health Organization. Available from: www.goldcopd com, 2007. Available from: www.goldcopd.com [Last accessed 4 March 2008]
   Google Scholar
• Rudolf M. The reality of drug use in COPD: the European perspective. Chest 2000;117:29S-32S
   Google Scholar
• Barnes PJ. Managing chronic obstructive pulmonary disease. London: Science Press, 1999
   Google Scholar
• de Jongste JC, Jongejan RC, Kerrebijn KF. Control of airway caliber by autonomic nerves in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis 1991;143:1421-6
   PubMedGoogle Scholar
• Disse B, Rominger K, Serby CW, et al. The pharmacokinetic (PK) profile of tiotropium during long-term treatment in stable COPD. Am J Respir Crit Care Med 1999;159:A524
   Google Scholar
• Disse B, Speck GA, Rominger KL, et al. Tiotropium (Spiriva™): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999;64:457-64
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Mechanisms in COPD. Differences from asthma. Chest 2000;117:10S-4S
   Web of Science ®Google Scholar
• Takahashi T, Belvisi MG, Patel H, et al. Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med 1994;150:1640-5
   PubMed Web of Science ®Google Scholar
• Chodosh S, Flanders JS, Kesten S, et al. Effective delivery of particles with the HandiHaler® dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J Aerosol Med 2001;14:309-15
   PubMedGoogle Scholar
• Voshaar T, Lapidus R, Maleki-Yazdi R, et al. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD. Respir Med 2008;102:32-41
   PubMed Web of Science ®Google Scholar
• van Noord JA, Cornelissen PJ, Aumann JL, et al. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir Med 2009;103:22-9
   PubMed Web of Science ®Google Scholar
• Türck D, Weber W, Sigmund R, et al. Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment. J Clin Pharmacol 2004;44:163-72
   PubMed Web of Science ®Google Scholar
• US food and drug administration. Spiriva HandiHaler (Tiotropium Bromide) inhalation powder. Center for drug evaluation and Research, 2008. Available from: http://www.fda.gov/cder/foi/nda/2004/21-395_Spiriva.htm [Last accessed 5 December 2008]
   Google Scholar
• Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54
   PubMed Web of Science ®Google Scholar
• Maesen FPV, Smeets JJ, Sledsens TJH, et al. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 1995;8:1506-13
   PubMed Web of Science ®Google Scholar
• Postma DS, Keyzer JJ, Koeter GH, et al. Influence of the parasympathetic and sympathetic nervous system on nocturnal bronchial obstruction. Clin Sci 1985;69:251-8
   PubMed Web of Science ®Google Scholar
• Celli B, Zuwallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003;124:1743-8
   PubMed Web of Science ®Google Scholar
• Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005;128:1168-78
   PubMed Web of Science ®Google Scholar
• Verkindre C, Bart F, Aguilaniu B, et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration 2006;73:420-7
   PubMed Web of Science ®Google Scholar
• Rice KL, Kunisaki KM, Niewoehner DE. Role of tiotropium in the treatment of COPD. Int J Chron Obstruct Pulmon Dis 2007;2:95-105
   PubMedGoogle Scholar
• Chen AM, Bollmeier SG, Finnegan PM. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease. Ann Pharmacother 2008;42:1832-42
   PubMed Web of Science ®Google Scholar
• Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 2006;130:1695-703
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim, Pfizer. Spiriva HandiHaler (tiotropium bromide inhalation powder): prescribing information. Available from: www spiriva com, 2008. Available from: http://www.spiriva.com/hcp/index.jsp [Last accessed 5 December 2008]
   Google Scholar
• Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:1439-50
   PubMed Web of Science ®Google Scholar
• de Luise C, Lanes SF, Jacobsen J, et al. Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark. Eur J Epidemiol 2007;22:267-72
   PubMed Web of Science ®Google Scholar
• Jara M, Lanes SF, Wentworth C III, et al. Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. Drug Saf 2007;30:1151-60
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272:1497-505
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Connett JE, Enright PL, Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002;166:333-9
   PubMed Web of Science ®Google Scholar
• Lanes S, Golisch W, Mikl J. Ipratropium and lung health study. Am J Respir Crit Care Med 2003;167:801-2
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55
   PubMed Web of Science ®Google Scholar